- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03192527
Single Dose Recombinant Human Follicle Stimulating Hormone Fc Husion Protein (KN015) in Healthy Volunteers
June 19, 2017 updated by: Alphamab Jilin Co., Ltd.
A Phase I, Randomized, Placebo Controlled, Single Ascending Dose (SAD) Study of Recombinant Human Follicle Stimulating Hormone Fc Fusion Protein (KN015) in Healthy Female Volunteers
KN015,the active substance recombinant human Follicle Stimulating Hormone(FSH) Fc fusion protein, which belongs to the pharmaceutical class gonadotropins.KN015 is proposed for Assisted Reproductive Technology (ART) programs only.
Its indication is Controlled Ovarian Stimulation (COS)in combination with a gonadotropin releasing hormone (GnRH) antagonist for the development of multiple follicles in women participating in an ART program.
Due to its prolonged duration of FSH activity compared to conventional recombinant FSH (rFSH), a single subcutaneous injection of the recommended dose of KN015 may replace any daily rFSH preparation in a COS treatment cycle.
This study is to evaluation of the safety, tolerability, pharmacokinetics and pharmacodynamics of KN015 in healthy Chinese female subjects.
Study Overview
Status
Unknown
Conditions
Intervention / Treatment
Detailed Description
This is a phase I, randomized, placebo-controlled, single ascending dose, double blind parallel design, first-in-human study.
The study design allows a gradual escalation of the dose-level with intensive safety monitoring to ensure the safety of the subjects.
Dose escalation will continue until identification of MTD or up to a maximum dose of 100 μg.
Tolerability, safety, pharmacokinetics (PK), pharmacodynamics (PD) and immunogenicity characteristics of KN015 will be assessed in healthy female subjects.
Eligible subjects will undergo down-regulation of endogenous FSH with a GnRH antagonist Triptorelin prior to receiving KN015.
Study Type
Interventional
Enrollment (Anticipated)
50
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Yanhua Ding, M.D.
- Phone Number: 86-0431-88782168
- Email: dingyanhua2003@126.com
Study Contact Backup
- Name: lei gao, M.D.
- Email: 398027192@qq.com
Study Locations
-
-
Jilin
-
Chuangchun, Jilin, China, 0431
- Recruiting
- The First Hospital of Jilin University
-
Contact:
- Yanhua Ding, M.D.
- Phone Number: 86-0431-88782168
- Email: dingyanhua2003@126.com
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 40 years (Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
Female
Description
Inclusion Criteria:
- Able and willing to provide written informed consent.
- Agreed to take effective contraceptive measures during and 6 months after the end of the study period.
- Age between 18 to 40 years (inclusive).
- Body weight ≥45 kg, body mass index (BMI) of ≥18 and ≤28 kg/m2,
- Regular menstruation cycle (25 to 34 days, inclusive).
- Healthy female volunteer, normal findings in medical history and physical examinations.
- Normal findings in sex hormone examinations unless the investigator considers an abnormality to be clinically irrelevant for this study.
- Negative for human immunodeficiency virus (HIV) I and II tests, hepatitis B surface antigen (HBsAg), hepatitis C antibody and schaudinn's bacillus antibody at screening.
- Normal uterus, presence of both ovaries, unless investigator considers an abnormality to be clinically irrelevant for this study.
Exclusion Criteria:
- Historic abuse of alcoholic beverages and drugs. Smoke ≥5 cigarettes or the equivalent per day. Drug screen will include the minimum the following: amphetamines, barbiturates, benzodiazepines, cannabis, cocaine, methadone, opiates.
- History of hypersensitivity to FSH, or any documented or suspected allergy to KN015 or the excipients of the KN015 formulation, or hypersensitivity to luteinizing hormone releasing hormone agonist or something like that.
- Any medical history of circulation, endocrine, nervous, digestive and respiratory systems, hematology, immunology, psychiatry and metabolic disorders and other serious disease history which can interfere with the test results of the study.
- Polycystic ovary syndrome (PCOS).
- Baseline of serum FSH ≥15 IU/L.
- History of ovarian hyperstimulation syndrome (OHSS).
- Experience in controlled ovarian stimulation (COS), or showed high response to FSH stimulation or the number of follicles over 11mm in diameter is more than 30.
- The history of ovarian, breast, uterus, hypothalamus, and pituitary disease was determined by the investigators as clinical meaningful. Previous history of thrombosis or tending to suffer from thrombotic disease.
- History of malignant disease.
- Failing to comply with the special requirements of diet during study.
- Participation in a clinical study within 3 months prior to the study.
- Any medical condition that, in the opinion of the investigator, would interfere with safety of the subject or with the objectives of the study.
- Abnormal physical examinational results which is determined as clinical significance by the researchers of the study.
- Abnormal vital signs and clinical significance.
- Aspartate aminotransferase (AST) and/or alanine aminotransferase (ALT) >1.5 x ULN.
- Thyroid dysfunction which clinical significance by researchers of the study.
- Other abnormal laboratory tests with clinically relevance.
- Abnormal electrocardiogram [ECG] findings.
- III/IV class endometriosis, submucous myoma of uterus, endocrine abnormalities within 6 months prior to the study.
- Abnormal imaging examination and clinical significance judged by researchers of the study.
- Pregnancy or lactation period.
- Alcohol and urine drug screening positive. -
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Arm A
KN015, Triptorelin
|
experimental drug
The drug is used for down-regulation of endogenous FSH.
|
Placebo Comparator: Arm B
placebo, Triptorelin
|
The drug is used for down-regulation of endogenous FSH.
Comparator.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Number of Participants With Abnormal Laboratory Values and/or Adverse Events That Are Related to Treatment(SAEs) and AEs of special interest.
Time Frame: From screening to up to 36 days
|
From screening to up to 36 days
|
Maximum observed serum concentration (Cmax) of KN015 in healthy Chinese female subjects
Time Frame: within 0.5 hour pre-dose, 2,5,8,12,24,30,36,40,48,54,60,72,96h,120,144,168,240,288,336,504,672 hours post-dose.
|
within 0.5 hour pre-dose, 2,5,8,12,24,30,36,40,48,54,60,72,96h,120,144,168,240,288,336,504,672 hours post-dose.
|
Time of Maximum observed serum concentration (Tmax) of KN015 in healthy Chinese female subjects.
Time Frame: within 0.5 hour pre-dose, 2,5,8,12,24,30,36,40,48,54,60,72,96h,120,144,168,240,288,336,504,672 hours post-dose.
|
within 0.5 hour pre-dose, 2,5,8,12,24,30,36,40,48,54,60,72,96h,120,144,168,240,288,336,504,672 hours post-dose.
|
Adjusted geometric means of area under the serum concentration-time curve from time zero to the time of last quantifiable concentration (AUC(0-T)) for KN015.
Time Frame: within 0.5 hour pre-dose, 2,5,8,12,24,30,36,40,48,54,60,72,96h,120,144,168,240,288,336,504,672 hours post-dose.
|
within 0.5 hour pre-dose, 2,5,8,12,24,30,36,40,48,54,60,72,96h,120,144,168,240,288,336,504,672 hours post-dose.
|
Adjusted geometric means of area under the serum concentration-time curve from time zero extrapolated to infinite time (AUC(INF)) for KN015.
Time Frame: within 0.5 hour pre-dose, 2,5,8,12,24,30,36,40,48,54,60,72,96h,120,144,168,240,288,336,504,672 hours post-dose.
|
within 0.5 hour pre-dose, 2,5,8,12,24,30,36,40,48,54,60,72,96h,120,144,168,240,288,336,504,672 hours post-dose.
|
Serum Half-life (T-HALF) of KN015 in healthy Chinese female subjects.
Time Frame: within 0.5 hour pre-dose, 2,5,8,12,24,30,36,40,48,54,60,72,96h,120,144,168,240,288,336,504,672 hours post-dose.
|
within 0.5 hour pre-dose, 2,5,8,12,24,30,36,40,48,54,60,72,96h,120,144,168,240,288,336,504,672 hours post-dose.
|
Serum clearance (CL) of KN015 in healthy Chinese female subjects.
Time Frame: within 0.5 hour pre-dose, 2,5,8,12,24,30,36,40,48,54,60,72,96h,120,144,168,240,288,336,504,672 hours post-dose.
|
within 0.5 hour pre-dose, 2,5,8,12,24,30,36,40,48,54,60,72,96h,120,144,168,240,288,336,504,672 hours post-dose.
|
Volume of distribution at steady state (VSS) of KN015 in healthy Chinese female subjects.
Time Frame: within 0.5 hour pre-dose, 2,5,8,12,24,30,36,40,48,54,60,72,96h,120,144,168,240,288,336,504,672 hours post-dose.
|
within 0.5 hour pre-dose, 2,5,8,12,24,30,36,40,48,54,60,72,96h,120,144,168,240,288,336,504,672 hours post-dose.
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
The number of follicles after dosing.
Time Frame: screening,-1,2,4,6,8,11,15,22,29,36 days post-dose
|
screening,-1,2,4,6,8,11,15,22,29,36 days post-dose
|
The size of follicles after dosing.
Time Frame: screening,-1,2,4,6,8,11,15,22,29,36 days post-dose
|
screening,-1,2,4,6,8,11,15,22,29,36 days post-dose
|
Determination of serum concentrations of FSH, E2, LH and P after dosing.
Time Frame: From screening to up to 36 days
|
From screening to up to 36 days
|
Percentage of participants with anti-KN015 antibody.
Time Frame: -1,8,15,36 days post-dose
|
-1,8,15,36 days post-dose
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Anticipated)
June 1, 2017
Primary Completion (Anticipated)
March 1, 2019
Study Completion (Anticipated)
June 1, 2019
Study Registration Dates
First Submitted
June 14, 2017
First Submitted That Met QC Criteria
June 19, 2017
First Posted (Actual)
June 20, 2017
Study Record Updates
Last Update Posted (Actual)
June 20, 2017
Last Update Submitted That Met QC Criteria
June 19, 2017
Last Verified
June 1, 2017
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- KNJR-2017-001
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
No
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Infertility, Female
-
Esraa Gamal AhmedAin Shams Maternity HospitalUnknownUnexplained Female Infertility
-
Pacific Fertility CenterTerminatedPrimary Female Infertility | Secondary Female Infertility
-
Assuta Hospital SystemsMaccabi Healthcare Services, IsraelCompletedInfertility, Female Infertility, Male InfertilityIsrael
-
Newlife Fertility CentreRecruitingInfertility | Infertility,Female | Infertility Unexplained | Infertility of Uterine Origin | Infertility; Female, NonimplantationCanada
-
Cairo UniversityCompleted
-
Navy General Hospital, BeijingUnknownFemale Infertility Due to Nonimplantation of OvumChina
-
Radboud University Medical CenterZonMw: The Netherlands Organisation for Health Research and DevelopmentCompletedPregnancy | Male Infertility | Female InfertilityNetherlands
-
Woman's Health University Hospital, EgyptCompletedFemale Infertility Due to Diminished Ovarian ReserveEgypt
-
Woman's Health University Hospital, EgyptCompleted
-
The University of Hong KongCompletedFemale Infertility Due to Diminished Ovarian ReserveHong Kong